<DOC>
	<DOCNO>NCT00112619</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , topotecan , work different way stop growth cancer cell , either kill cell stop dividing . PURPOSE : This phase I trial study side effect , best way give , best dose topotecan give intraventricular infusion treat young patient neoplastic meningitis due leukemia , lymphoma , solid tumor .</brief_summary>
	<brief_title>Topotecan Treating Young Patients With Neoplastic Meningitis Due Leukemia , Lymphoma , Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) intraventricular topotecan young patient neoplastic meningitis secondary leukemia , lymphoma , solid tumor . - Determine toxic effect dose-limiting toxicity drug patient . - Determine whether MTD drug also pharmacokinetic optimal dose , define topotecan lactone concentration cerebral spinal fluid ( CSF ) , patient . Secondary - Determine , preliminarily , antitumor activity drug patient . - Determine pharmacokinetics drug CSF patient . - Correlate observed effect post-treatment central review imaging ( feasible ) response drug patient . OUTLINE : This non-randomized , dose-escalation , multicenter study . - Induction therapy ( week 1-4 ) : Patients receive topotecan intraventricularly* 5 minute day 1-5 week 1 3 . Patients proceed consolidation therapy week 5 . NOTE : *Patients willing , receive 1 intralumbar ( instead intraventricular ) dose topotecan day 1 week 3 . - Consolidation therapy ( week 5-10 ) : Patients receive topotecan intraventricularly day 1-5 week 5 8 . Patients proceed maintenance therapy week 11 . - Maintenance therapy ( week 11-54 ) : Patients receive topotecan intraventricularly day 1-5 week 11 , 15 , 19 , 23 , 27 , 31 , 35 , 39 , 43 , 47 , 51 . Cohorts 3-6 patient receive escalate dos intraventricular topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , cohort expand 25 patient MTD declare pharmacokinetic optimal dose provide 23 25 patient treat MTD achieve target pharmacokinetic parameter . PROJECTED ACCRUAL : A total 28-49 patient accrue study within 9-24 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis neoplastic meningitis secondary leukemia , lymphoma ( include AIDSrelated lymphoma ) , solid tumor ( include primary CNS tumor carcinomas unknown primary site ) , define 1 follow criterion : Cerebral spinal fluid ( CSF ) cell count &gt; 5/μL AND evidence blast cell cytospin cytology ( patient leukemia lymphoma ) Presence tumor cell cytospin cytology OR unequivocal presence meningeal disease MRI ( patient solid tumor ) No conventional therapy neoplastic meningitis exist Patients CNS leukemia lymphoma must refractory conventional therapy , include radiotherapy ( i.e. , second great relapse ) Patients CNS leukemia lymphoma must negative bone marrow aspiration within past 2 week No clinical evidence obstructive hydrocephalus No compartmentalization CSF flow radioisotope indium In 111 technetium Tc 99 DTPA flow study No ventriculoperitoneal ventriculoatrial shunt unless patient completely shuntindependent No impend spinal cord compression CNS involvement ( e.g. , acute visual loss secondary optic nerve involvement ) require emergent local radiotherapy PATIENT CHARACTERISTICS : Age 3 21 Performance status Lansky 60100 % ( ≤ 16 year age ) OR Karnofsky 60100 % ( &gt; 16 year age ) Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Calcium ≥ 7 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Sodium 125150 mmol/L Magnesium ≥ 0.7 mmol/L Must willing intraventricular access device ( i.e. , Ommaya reservoir ) No uncontrolled infection HIVpositive patient AIDSrelated lymphomatous meningitis eligible No significant uncontrolled systemic medical illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Recovered prior biologic therapy immunotherapy Chemotherapy Recovered prior chemotherapy At least 1 week since prior intracolony stimulate factory ( CSF ) chemotherapy ( 2 week liposomal cytarabine ) At least 3 week since prior systemic chemotherapy leptomeningeal disease Concurrent systemic chemotherapy control systemic disease bulk CNS disease allow provided systemic chemotherapy investigational agent OR following : Highdose ( &gt; 1 g/m^2 ) methotrexate Highdose ( &gt; 1 g/m^2 ) cytarabine Fluorouracil Capecitabine Thiotepa Nitrosoureas Topotecan Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 8 week since prior craniospinal radiotherapy recover No concurrent CNS radiotherapy Concurrent radiotherapy extraCNS site ( e.g. , painful bone metastases craniospinal axis ) allow Surgery Not specify Other More 2 week since prior concurrent investigational agent No concurrent intraCSF systemic therapy leptomeningeal disease</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>AIDS-related diffuse small cleave cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related lymphoblastic lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
	<keyword>HIV-associated Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>primary central nervous system Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>childhood grade I meningioma</keyword>
	<keyword>childhood grade II meningioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>leptomeningeal metastasis</keyword>
	<keyword>recurrent carcinoma unknown primary</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>recurrent childhood pineoblastoma</keyword>
	<keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
	<keyword>meningeal leukemia</keyword>
	<keyword>secondary central nervous system Hodgkin lymphoma</keyword>
	<keyword>secondary central nervous system non-Hodgkin lymphoma</keyword>
</DOC>